Capital International Investors cut its stake in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Free Report) by 70.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 253,495 shares of the biotechnology company’s stock after selling 610,291 shares during the quarter. Capital International Investors owned 0.14% of Cerevel Therapeutics worth $10,715,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors also recently modified their holdings of the company. Avoro Capital Advisors LLC boosted its holdings in shares of Cerevel Therapeutics by 690.7% in the fourth quarter. Avoro Capital Advisors LLC now owns 7,555,555 shares of the biotechnology company’s stock worth $320,356,000 after acquiring an additional 6,600,000 shares during the period. Bain Capital Investors LLC raised its position in shares of Cerevel Therapeutics by 9.1% in the fourth quarter. Bain Capital Investors LLC now owns 65,679,781 shares of the biotechnology company’s stock worth $2,784,823,000 after buying an additional 5,480,052 shares in the last quarter. Alpine Associates Management Inc. purchased a new stake in shares of Cerevel Therapeutics in the fourth quarter worth $69,710,000. Vanguard Group Inc. raised its position in shares of Cerevel Therapeutics by 15.8% in the fourth quarter. Vanguard Group Inc. now owns 7,374,970 shares of the biotechnology company’s stock worth $312,699,000 after buying an additional 1,003,594 shares in the last quarter. Finally, Perceptive Advisors LLC raised its position in shares of Cerevel Therapeutics by 8.7% in the fourth quarter. Perceptive Advisors LLC now owns 10,965,193 shares of the biotechnology company’s stock worth $464,924,000 after buying an additional 876,808 shares in the last quarter. 87.73% of the stock is owned by institutional investors.
Cerevel Therapeutics Price Performance
Shares of CERE stock traded up $0.22 on Friday, reaching $44.62. The company’s stock had a trading volume of 1,974,794 shares, compared to its average volume of 1,601,674. The company has a quick ratio of 10.22, a current ratio of 10.22 and a debt-to-equity ratio of 0.60. Cerevel Therapeutics Holdings, Inc. has a 12-month low of $19.59 and a 12-month high of $44.66. The company has a market capitalization of $8.13 billion, a P/E ratio of -16.34 and a beta of 1.40. The stock’s 50 day simple moving average is $41.39 and its 200-day simple moving average is $41.84.
Insider Activity
In related news, Director N Anthony Coles sold 25,000 shares of the firm’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $41.18, for a total value of $1,029,500.00. Following the sale, the director now directly owns 25,928 shares of the company’s stock, valued at $1,067,715.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 5.10% of the company’s stock.
Cerevel Therapeutics Company Profile
Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model.
Further Reading
- Five stocks we like better than Cerevel Therapeutics
- How to Invest in the Best Canadian Stocks
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- Upcoming IPO Stock Lockup Period, Explained
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- How to Most Effectively Use the MarketBeat Earnings Screener
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Want to see what other hedge funds are holding CERE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Free Report).
Receive News & Ratings for Cerevel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerevel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.